Adam Sayer Takes the Helm of Lyndra Therapeutics
Lyndra Therapeutics, a pioneering clinical-stage biopharmaceutical company specializing in long-acting oral therapies, is excited to announce the appointment of Adam Sayer as the new President and Chief Executive Officer. This strategic leadership change signifies a pivotal moment for the company, as Sayer brings significant experience and vision to the role.
Expertise Shaping the Future
Before stepping into his new role, Sayer served as the Chief Transformation Officer at Envision Healthcare. There, he excelled in overseeing strategy, transformation efforts, and payer negotiations. His extensive knowledge in the healthcare domain, along with a proven track record of operational excellence, positions him uniquely to drive forward Lyndra’s ambitious programs, including the compelling oral weekly risperidone (LYN-005).
His previous roles have equipped him with a deep understanding of the healthcare ecosystem—a quality that is expected to be vital in advancing Lyndra’s mission to bring groundbreaking long-acting oral therapeutics to patients.
A Vision of Transformation
“Joining Lyndra at this critical moment is a thrilling opportunity,” remarked Sayer. “The company’s innovative LYNX platform technology symbolizes a breakthrough in oral medicine delivery, potentially revolutionizing patient outcomes. I am eager to lead this talented team as we advance our mission to deliver the first long-acting oral medicines to the market.”
Continuity and Progress
Former President and CEO Jessica Ballinger has paved an impressive path for Lyndra, overseeing critical initiatives during her tenure. She led the successful completion of the pivotal efficacy study for LYN-005 and initiated a significant collaboration with Thermo Fisher Scientific for comprehensive clinical research and manufacturing services.
Her contributions have firmly set the stage for Lyndra to continue its momentum in innovation and development, allowing Sayer to build upon this strong foundation.
A Strong Leadership Team
As Amy Schulman, co-founder and Executive Chair of the Board, expressed gratitude for Ballinger's leadership, she is equally optimistic about what Sayer brings to the table: “Under Adam’s guidance and with his commitment to precise execution, Lyndra Therapeutics is well-positioned to achieve its goals and to redefine how oral medicines are delivered to patients.”
A Bright Future Ahead
Adam Sayer’s appointment is not just a change at the executive level; it reflects Lyndra’s broader strategic intent to innovate in long-acting oral therapies, a crucial area in biopharmaceutical advancements. The upcoming pivotal safety study for LYN-005 is scheduled to launch in the near future, with an optimistic outlook aimed at substantially improving patient care through these transformative therapies.
About Lyndra Therapeutics
Lyndra Therapeutics is committed to enhancing the delivery of medications through its innovative LYNX platform. This unique drug delivery system offers the advantage of administering medicine in a single dose that lasts for an entire week or longer. By minimizing dosing frequencies, Lyndra aims to provide a more stable drug exposure, thus enhancing the patient experience significantly.
The versatility of the LYNX platform has been validated through clinical research spanning across five therapeutic areas and 25 active pharmaceutical ingredients (APIs). With an unwavering focus on partnership opportunities, Lyndra Therapeutics continues to forge pathways to improve patient outcomes, demonstrating that the future of medication delivery is indeed here. For more insights and information on potential partnerships, visit https://lyndra.com.
Frequently Asked Questions
Who is the new CEO of Lyndra Therapeutics?
Adam Sayer has been appointed as the new President and CEO of Lyndra Therapeutics.
What is the focus of Lyndra Therapeutics?
Lyndra Therapeutics specializes in developing innovative long-acting oral therapies to enhance medication delivery and patient outcomes.
What was Adam Sayer's role before joining Lyndra?
He served as the Chief Transformation Officer at Envision Healthcare, overseeing strategy and operational transformation.
What is the LYNX platform technology?
The LYNX platform technology enables long-acting oral medications, allowing a single dose to provide therapeutic benefits for a week or longer.
When will the safety study for LYN-005 begin?
The pivotal safety study for LYN-005 is scheduled to start in the first half of 2025.
